Tag
IL-6 receptor inhibition during hematopoietic stem cell transplantation fosters type I interferon responses and promotes expansion of cytolytic CD4+ T cells, including Eomes+ subsets, augmenting antitumor immunity while mitigating graft-ver
This case series examines immunosuppressive management and long-term outcomes in nine Japanese patients undergoing single living-donor lobar lung transplantation from the same donor as prior HSCT, revealing viable reduced immunosuppression
PPM1D mutations and overexpression are involved in MPN pathogenesis, with dual PPM1D and HDM2 inhibition emerging as a promising therapeutic strategy, particularly for myelofibrosis patients.
This multicenter study reveals that total-body irradiation (TBI) conditioning before hematopoietic stem cell transplantation severely compromises pregnancy outcomes compared to alkylating agents or conventional chemotherapy in female surviv
This retrospective multicenter study evaluates fecal microbiota transplantation (FMT) for steroid-refractory acute graft-versus-host disease (aGvHD), demonstrating a 60.5% response at day 28 and highlighting FMT’s potential as a safe
A French longitudinal study finds no increased long-term complications or compromised quality of life in children under 4 years undergoing TBI-based HSCT for acute lymphoblastic leukemia, challenging prior age restrictions.
This study evaluates ovarian tissue cryopreservation (OTC) feasibility in girls and young women post-hematopoietic stem cell transplantation (HSCT), demonstrating OTC as a potential fertility salvage option despite reduced ovarian reserve a
This review synthesizes evidence revealing l-carnitine’s pivotal role in human hematopoietic stem and progenitor cell regeneration via fatty acid oxidation, highlighting metabolic profiling advances and translational potential for reg
A prospective multicenter study reports excellent survival, no graft failure, and very low GVHD with a thiotepa-based reduced-intensity matched sibling transplant platform for severe sickle cell disease.
A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.
A clinical study comparing OTL-203 gene therapy to allogeneic HSCT for Hurler syndrome reveals significant improvements in corneal clarity, hearing preservation, and cardiac stability, marking a potential shift in the standard of care for m
The FANCOLEN‑1 trial shows that infusion of autologous FANCA‑corrected CD34+ cells without cytotoxic conditioning produced sustained engraftment and clinical improvement in a majority of treated patients with Fanconi anaemia‑A, with an acce
Inpatient palliative care during hematopoietic stem cell transplantation improves patients’ quality of life, reduces depression and PTSD symptoms, and offers sustained psychological benefits up to six months post-transplant.
Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease prophylaxis significantly improves 1-year survival and lowers severe GVHD rates in mismatched unrelated donor peripheral blood stem cell transplants, expanding access for
